164 related articles for article (PubMed ID: 20706839)
1. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
[TBL] [Abstract][Full Text] [Related]
3. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Odenike O; Halpern A; Godley LA; Madzo J; Karrison T; Green M; Fulton N; Mattison RJ; Yee KW; Bennett M; Koval G; Malnassy G; Larson RA; Ratain MJ; Stock W
Invest New Drugs; 2015 Apr; 33(2):371-9. PubMed ID: 25483416
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
[TBL] [Abstract][Full Text] [Related]
8. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS
Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
12. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.
Peer CJ; Hall OM; Sissung TM; Piekarz R; Balasubramaniam S; Bates SE; Figg WD
Cancer Chemother Pharmacol; 2018 Sep; 82(3):565-570. PubMed ID: 29951694
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
[TBL] [Abstract][Full Text] [Related]
14. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
[TBL] [Abstract][Full Text] [Related]
15. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
[TBL] [Abstract][Full Text] [Related]
16. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
Goey AK; Sissung TM; Peer CJ; Trepel JB; Lee MJ; Tomita Y; Ehrlich S; Bryla C; Balasubramaniam S; Piekarz R; Steinberg SM; Bates SE; Figg WD
J Clin Pharmacol; 2016 Apr; 56(4):461-73. PubMed ID: 26313268
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Balasubramaniam S; Redon CE; Peer CJ; Bryla C; Lee MJ; Trepel JB; Tomita Y; Rajan A; Giaccone G; Bonner WM; Figg WD; Fojo T; Piekarz RL; Bates SE
Anticancer Drugs; 2018 Jun; 29(5):457-465. PubMed ID: 29420340
[TBL] [Abstract][Full Text] [Related]
19. Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Burhenne J; Liu L; Heilig CE; Meid AD; Leisen M; Schmitt T; Kasper B; Haefeli WE; Mikus G; Egerer G
Cancer Chemother Pharmacol; 2017 Aug; 80(2):433-439. PubMed ID: 28612091
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the effect of belinostat in solid tumors by H4 acetylation.
Marquard L; Petersen KD; Persson M; Hoff KD; Jensen PB; Sehested M
APMIS; 2008 May; 116(5):382-92. PubMed ID: 18452428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
